TY - JOUR
T1 - Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus
T2 - Down-regulation by the tolerogeneic peptide hCDR1
AU - Sthoeger, Zev
AU - Sharabi, Amir
AU - Zinger, Heidy
AU - Asher, Ilan
AU - Mozes, Edna
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/12
Y1 - 2018/12
N2 - וֹndoleamine-2,3-dioxygenase (IDO) plays a role in immune regulation. Increased IDO activity was reported in systemic lupus erythematosus (SLE). We investigated the effects of the tolerogenic peptide hCDR1, shown to ameliorate lupus manifestations, on IDO gene expression. mRNA was prepared from splenocytes of hCDR1- treated SLE-afflicted (NZBxNZW)F1 mice, from blood samples of lupus patients, collected before and after their in vivo treatment with hCDR1 and from peripheral blood mononuclear cells (PBMC) of patients incubated with hCDR1. IDO gene expression was determined by real-time RT-PCR. hCDR1 significantly down-regulated IDO expression in SLE-affected mice and in lupus patients (treated in vivo and in vitro). No effects were observed in healthy donors or following treatment with a control peptide. Diminished IDO gene expression was associated with hCDR1 beneficial effects. Our results suggest that the hCDR1-induced FOXP3 expressing regulatory T cells in lupus are not driven by IDO but rather by other hCDR1 regulated pathways.
AB - וֹndoleamine-2,3-dioxygenase (IDO) plays a role in immune regulation. Increased IDO activity was reported in systemic lupus erythematosus (SLE). We investigated the effects of the tolerogenic peptide hCDR1, shown to ameliorate lupus manifestations, on IDO gene expression. mRNA was prepared from splenocytes of hCDR1- treated SLE-afflicted (NZBxNZW)F1 mice, from blood samples of lupus patients, collected before and after their in vivo treatment with hCDR1 and from peripheral blood mononuclear cells (PBMC) of patients incubated with hCDR1. IDO gene expression was determined by real-time RT-PCR. hCDR1 significantly down-regulated IDO expression in SLE-affected mice and in lupus patients (treated in vivo and in vitro). No effects were observed in healthy donors or following treatment with a control peptide. Diminished IDO gene expression was associated with hCDR1 beneficial effects. Our results suggest that the hCDR1-induced FOXP3 expressing regulatory T cells in lupus are not driven by IDO but rather by other hCDR1 regulated pathways.
KW - Cytokines
KW - FOXP3
KW - Immunomodulation of gene expression
KW - Indoleamine 2,3-dioxygenase (IDO)
KW - Systemic lupus erythematosus (SLE)
KW - Tolerogenic peptide (hCDR1)
UR - http://www.scopus.com/inward/record.url?scp=85052860366&partnerID=8YFLogxK
U2 - 10.1016/j.clim.2018.08.012
DO - 10.1016/j.clim.2018.08.012
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30170030
AN - SCOPUS:85052860366
SN - 1521-6616
VL - 197
SP - 34
EP - 39
JO - Clinical Immunology
JF - Clinical Immunology
ER -